AlliThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you your search results in order of date.

Pages: 1 2 3 4 5 6 7 8 9 10

481 records returned

Viagra: The profitable pillEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
When Pfizer launched Viagra in 1998 its share price doubled within days. Since then, the little blue pills have become a pillar of profit, earning the company more than £1bn a year.Thanks to promotional campaigns, which included appearances by the footballing legend Pele, male impotence lost some of its stigma and 25 million men requested the pills. In England alone, GPs write about 6m Viagra prescriptions a year.The drug started life in a lab in Sandwich, Kent, where it was developed to treat high blood pressure. Its transformation into a blockbuster treatment for impotence began when volunteers in a clinical trial repor...
Source: Guardian Unlimited Science - November 16, 2009 Category: Science Authors: Ian Sample Tags: Pharmaceuticals industry Science Business Drugs Reproduction Medical research Sexual health Society The Guardian News Source Type: news

Efficacy and Safety of Ezetimibe Plus Orlistat or Rimonabant in Statin-Intolerant Nondiabetic Overweight/Obese Patients With DyslipidemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: For similar body weight reduction, the combination of ezetimibe with orlistat may be more efficient in LDL-C lowering, whereas the combination of ezetimibe with rimonabant may be more potent in terms of improving HDL-C and triglycerides. (Source: Journal of Cardiovascular Pharmacology and Therapeutics)
Source: Journal of Cardiovascular Pharmacology and Therapeutics - November 11, 2009 Category: Cardiology Authors: Florentin, M., Kostapanos, M. S., Nakou, E. S., Elisaf, M., Liberopoulos, E. N. Tags: Articles Source Type: journals

Misused Weight-Loss DrugEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
So you create a weight-loss drug, Alli, and put it in an environment in which it's supposed to be given to people who are overweight...and then it ends up in the hands of people who aren't overweight. It's not a case of people getting the stuff on some kind of black market. It's people buying it over the counter in Ireland. According to licensing conditions, pharmacists in Ireland can't sell Alli to anyone who's of normal weight or underweight. But eight out of 20 pharmacies sold the drug to a researcher who is well under the "overweight" threshold. Not a good situation. But I wonder: How is a customer supposed to verify...
Source: About.com Eating Disorders - November 9, 2009 Category: Eating Disorders and Weight Management Source Type: consumer

[Comment] Gastrointestinal hormones and weight managementEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The gastrointestinal tract produces several peptide hormones that participate in regulation of food intake. Some, such as cholecystokinin, glucagon-like peptide-1 (GLP-1), polypeptide YY(3–36), and oxyntomodulin, decrease food intake, and at least one, ghrelin, increases food intake. Such effects indicate that agonists and antagonists to these hormones would make interesting targets for drug treatment of obesity. In The Lancet today, Arne Astrup and colleagues report on use of the GLP-1 agonist liraglutide as a treatment for obesity, by comparison with orlistat, an approved treatment that blocks intestinal lipase, and pl...
Source: LANCET - November 6, 2009 Category: Journals (General) Authors: George A Bray Tags: Comment Source Type: journals

Fears emerge over weight-loss drug's links with kidney damageEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
THE EUROPEAN Medicines Agency has recommended the product information for the widely used weight-loss drug Alli be updated after kidney and pancreatic problems were reported in a number of patients using the drug. (Source: The Irish Times - Health)
Source: The Irish Times - Health - November 3, 2009 Category: Consumer Health News Source Type: news

DTB reviews place of OTC orlistat in the management of obesityEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: Drug and Therapeutics Bulletin Area: Evidence > Drug Specific Reviews The November 2009 issue of the Drug and Therapeutics Bulletin (DTB) features a review of OTC orlistat (alli®), which is available in the UK for purchase from pharmacies by adults who are overweight or obese (BMI ?28kg/m2), at a cost of around £55 per month (for up to 6 months). The review covers how it is being sold, practice guidance/training for pharmacists, efficacy data, unwanted effects and its cautions and contra-indications. The authors conclude that OTC orlistat 'provides a reasonable choice for motivated individuals w...
Source: NeLM - Drug Specific Reviews - November 3, 2009 Category: Drugs & Pharmacology Source Type: organizations

CHMP recommends updating OTC orlistat (alli®) product informationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: EMEA Area: News Following assessment of information related to levothyroxine, antiepileptics interactions and adverse events related to pancreatitis and oxalate nephropathy associated with OTC orlistat (alli®), the CHMP recommended updating the product information to reflect that patients taking medicines such as levothyroxine and antiepileptic drugs or patients with kidney disease should consult a doctor before starting treatment and that oxalate nephropathy and pancreatitis have been reported in a number of patients taking this medicine. The CHMP and Glaxo Group Ltd have agreed on a Direct Healthcare Pr...
Source: NeLM - News - November 2, 2009 Category: Drugs & Pharmacology Source Type: organizations

Swine flu vaccine shots eliminate wrinkles, bad breath and varicose veins, too (opinion)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(NaturalNews) The propaganda push for flu vaccines has reached a level of absurdity that's just begging to be made fun of. Today, a flu vaccine story appearing in Reuters claimed that injecting pregnant women with flu shots would increase the birth weight of their babies by half a pound. That same story claimed flu shots are so healthy for pregnant women that they also prevent premature births.It even quotes a team of experts who claim that injecting an expectant mother with a flu shot would reduce the hospitalization of her infants, explaining: "Flu vaccine given to women during pregnancy is 85 percent effective in preven...
Source: NaturalNews.com - October 30, 2009 Category: Consumer Health Advice Source Type: news

The C type natriuretic peptide receptor tethers AHNAK1 at the plasma membrane to potentiate arachidonic acid-induced calcium mobilizationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Arachidonic acid (AA) liberated from membrane phospholipids is known to activate phospholipase C 1 (PLC1) concurrently with AHNAK in nonneuronal cells. The recruitment of AHNAK from the nucleus is required for it to activate PLC1 at the plasma membrane. Here, we identify the C-type natriuretic peptide receptor (NPR-C), an atypical G protein-coupled receptor, as a protein binding partner for AHNAK1 in various cell types. Mass spectrometry and MASCOT analysis of excised bands from NPR-C immunoprecipitation studies revealed multiple signature peptides corresponding to AHNAK1. Glutathione S-transferase (GST) pulldown assays us...
Source: AJP: Cell Physiology - October 29, 2009 Category: Cytology Authors: Alli, A. A., Gower, W. R. Tags: RECEPTORS AND SIGNAL TRANSDUCTION Source Type: journals

Diabetes drug liraglutide 'better than orlistat and placebo for weight loss'Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A daily injection with liraglutide – the latest incretin drug for diabetes - is better at promoting weight loss than orlistat and placebo, alongside diet and exercise, a new study has found. (Source: Pulse)
Source: Pulse - October 26, 2009 Category: Primary Care Tags: News Source Type: news

OrlistatEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
No Abstract. (Source: Practical Diabetes International)
Source: Practical Diabetes International - October 26, 2009 Category: Endocrinology Authors: M Hall, M Fisher, G McKay Tags: Drug Notes Source Type: journals

Liraglutide Reduces Weight And Risk Factors In Obese People Without Diabetes (Online First)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Liraglutide reduces weight and the prevalence of risk factors in obese people without diabetes. Furthermore, high doses of liraglutide cause greater weight loss than orlistat. These are the conclusions of an Article published Online First (http://www.thelancet. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 25, 2009 Category: Consumer Health News Tags: Obesity / Weight Loss / Fitness Source Type: news

Health News of the DayEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
is a daily summary made from the selected links I post on Twitter. It is in a bullet points format with links to the original sources which include 350 RSS feeds that produce about 2,500 items per day:Meta-analysis finds 6-13% increased risk of diabetes in those who received statin therapy http://bit.ly/3iX7vd -- Although statin therapy greatly lowers vascular risk, relationship of statins to incident diabetes remains uncertain http://bit.ly/3BFQv5 -- "Statin-Induced Diabetes" - the headline of this editorial may be a bit premature considering the available evidence http://bit.ly/15L33KDiabetes drug liraglutide contains a...
Source: Clinical Cases and Images - October 24, 2009 Category: Journals (General) Tags: Health News of the Day Source Type: info

Diabetes drug helps obese adults loss weightEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NEW YORK (Reuters Health) - Obese adults may shed more weight with the diabetes drug liraglutide than with the weight-loss drug orlistat (Xenical, Alli), suggests a study in The Lancet this week. (Source: Reuters: Health)
Source: Reuters: Health - October 23, 2009 Category: Consumer Health News Tags: healthNews Source Type: news

Diabetes injection more effective that orlistat for weight lossEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Medical trials have revealed a diabetes injection, tested at 19 different hospitals, appears to help weight loss more than leading anti-obesity druh orlistat. (Source: Nursing Times Breaking News)
Source: Nursing Times Breaking News - October 23, 2009 Category: Nursing Source Type: news

Diabetes injection more effective than orlistat for weight lossEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Medical trials have revealed a diabetes injection, tested at 19 different hospitals, appears to help weight loss more than leading anti-obesity druh orlistat. (Source: Nursing Times Breaking News)
Source: Nursing Times Breaking News - October 23, 2009 Category: Nursing Source Type: news

Diabetes drug 'trumps fat pill' (BBC News online, 23 October 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A study published in the Lancet shows that patients treated with the diabetes drug liraglutide were significantly more likely to lose weight than those taking orlistat, a leading obesity drug. Full article (Source: Society for Endocrinology)
Source: Society for Endocrinology - October 23, 2009 Category: Endocrinology Source Type: organizations

Weight loss pills vs anti-fat jabEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
“Patients given a new anti-obesity drug lost more than a stone in weight in five months,” said The Times. The injectable drug, liraglutide, was reported as being almost twice as effective as other treatments in the study. The Daily Mail wrongly reports that the drug has been licensed for use in obese patients in the UK since July. In this high-quality randomised trial, 564 obese or severely obese patients were injected with either 1.2mg to 3.0mg of liraglutide a day, a daily 'dummy' jab, or orlistat pills three times a day. All patients followed a calorie-restricted diet and increased their physical activity. Contrary ...
Source: NHS News Feed - October 23, 2009 Category: Consumer Health News Tags: Obesity Medication Source Type: news

Obese People Without Diabetes: Liraglutide Reduces Weight And Prevalence Of Risk FactorsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
An article published Online First and in a future edition of The Lancet reports that liraglutide reduces weight and the prevalence of risk factors in obese people without diabetes. In addition, high doses of liraglutide cause greater weight loss than orlistat. The article is the work of Professor Arne Astrup, Department of Human Nutrition, University of Copenhagen, Denmark, and colleagues. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 23, 2009 Category: Consumer Health News Tags: Obesity / Weight Loss / Fitness Source Type: news

Journal Scan: Effects of Liraglutide in the Treatment of Obesity: A Randomised, Double-Blind, Placebo-Controlled Study (Lancet 2009;Oct 23:[Epub ahead of print].)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A double-blind, placebo-controlled, 20-week trial was conducted with an open-label orlistat comparator in 19 sites in Europe. A total of 564 individuals (18-65 years of age, body mass index 30-40 kg/m2) were randomly assigned, with a telephone or web-based system, to one of four liraglutide doses (1. . . (Source: Cardiosource)
Source: Cardiosource - October 23, 2009 Category: Cardiology Source Type: organizations

RCT: Liraglutide in the treatment of obesityEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study was then followed by an 84-week open-label extension. According to the intention to treat analysis: . The liraglutide group lost statistically significantly more weight than the ... (Source: NeLM - News)
Source: NeLM - News - October 22, 2009 Category: Drugs & Pharmacology Source Type: organizations

GLP-1 analog liraglutide promising in obesityEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A drug originally developed to treat diabetes may have promise as an obesity therapy, a new study shows. Those taking liraglutide, a GLP-1 analog, lost more weight than those on an established obesity medication, orlistat. (Source: theHeart.org)
Source: theHeart.org - October 22, 2009 Category: Cardiology Source Type: info

GLP-1 Analog Liraglutide Promising in ObesityEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A drug originally developed to treat diabetes may have promise as an obesity therapy, a new study shows. Those taking liraglutide, a GLP-1 analog, lost more weight than those on an established obesity medication, orlistat. Heartwire (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 22, 2009 Category: Consumer Health News Tags: Cardiology Source Type: news

Optical urethrotomy under local anaesthesia is a feasible option in urethral stricture disease.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The aim of our study was to assess the feasibility of performing optical urethrotomy for urethral stricture disease under local anaesthesia. A total of 33 patients with radiologically proven urethral stricture underwent optical urethrotomy by a single operator under local anaesthesia. Of these patients, 23 (70%) had stricture involving the corpora spongiosum and 18 (55%) of the patients were dependent on supra-pubic catheters. The procedure was successful in 30 cases (91%). The procedure was very well tolerated (average visual analogue pain score of 2/10) with an extremely low complication rate. The large number of pat...
Source: Tropical Doctor - October 22, 2009 Category: Tropical Medicine Authors: Munks DG, Alli MO, Goad EH Tags: Trop Doct Source Type: journals

Patient Characteristics in Behcet Disease: A Retrospective Analysis of 213 Turkish Patients during 20014Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - October 16, 2009 Category: Dermatology Authors: Alli, NuranGur, GunesYalcin, BasakHayran, Mutlu Tags: Original Research Article Source Type: journals

Role of Fat Hydrolysis in Regulating Glucagon-Like Peptide-1 Secretion.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: Generation of long-chain fatty acids through hydrolysis of fat is a critical step for fat-induced stimulation of GLP-1 in humans; the signal is mediated via CCK release and CCK-1 receptors. PMID: 19837920 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - October 15, 2009 Category: Endocrinology Authors: Beglinger S, Drewe J, Schirra J, Göke B, D'Amato M, Beglinger C Tags: J Clin Endocrinol Metab Source Type: journals

What extent of weight loss can benefit the health-related quality of life in motivated obese Chinese?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: The extent, not the type of intervention, of weight loss is highly correlated with the favorable changes in HRQOL at 6-months. Weight loss above 5% of baseline values is necessary to show significant improvements in HRQOL in motivated obese Chinese. PMID: 19786391 [PubMed - in process] (Source: Asia Pacific Journal of Clinical Nutrition)
Source: Asia Pacific Journal of Clinical Nutrition - October 2, 2009 Category: Nutrition Authors: Wu CH, Kuo HC, Chang CS, Yu C Tags: Asia Pac J Clin Nutr Source Type: journals

What are the risks and the benefits of current and emerging weight-loss medications?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This article discusses the perceived benefits and risks of these approved medications along with emerging drugs that have shown weight-loss effects. Content Type Journal ArticleDOI 10.1007/s11892-009-0058-xAuthors Jamie R. RobinsonKevin D. Niswender, Vanderbilt University Medical Center Department of Medicine, Molecular Physiology and Biophysics 7435G MRB IV Nashville TN 37232 USA Journal Current Diabetes ReportsOnline ISSN 1539-0829Print ISSN 1534-4827 Journal Volume Volume 9 Journal Issue Volume 9, Number 5 / October, 2009 (Source: Current Diabetes Reports)
Source: Current Diabetes Reports - September 29, 2009 Category: Endocrinology Tags: Current Diabetes Reports Source Type: journals

Regimen promotes orlistat efficacy in teensEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Kim J. Masters, MD (Source: Pearls)
Source: Pearls - September 24, 2009 Category: Psychiatry Source Type: journals

FDA Issues Early Communication About Ongoing Safety Review of Weight Loss Drug OrlistatEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The US Food and Drug Administration (FDA) announced that it is reviewing new safety information regarding reports of liver-related adverse events in patients taking orlistat. Orlistat is marketed in the United States as a prescription product, Xenical, and as an over-the-counter (OTC) product, Alli. (Source: Gastroenterology)
Source: Gastroenterology - September 22, 2009 Category: Gastroenterology Authors: Leslie H. Lang Tags: Gastroenterology and Hepatology News Source Type: journals

An orlistat “overdose” in a childEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s11845-009-0429-yAuthors M. B. O’Connor, Mallow General Hospital Department of Medicine Mallow Ireland Journal Irish Journal of Medical ScienceOnline ISSN 1863-4362Print ISSN 0021-1265 (Source: Irish Journal of Medical Science)
Source: Irish Journal of Medical Science - September 17, 2009 Category: Journals (General) Tags: Irish Journal of Medical Science Source Type: journals

News from the FDAEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Reports of liver injury, including liver failure, in people taking OTC and prescription orlistat for weight loss are being investigated by the Food and Drug Administration, the agency announced. (Source: Family Practice News)
Source: Family Practice News - September 14, 2009 Category: Primary Care Authors: From staff reports Tags: News from the FDA Source Type: news

FDA issues early communication about ongoing safety review of orlistatEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
FDA is reviewing reports of liver injury in patients treated with orlistat (prescription drug, Xenical; OTC drug, Alli) for obesity management or weight loss. (Source: Modern Medicine)
Source: Modern Medicine - September 13, 2009 Category: Journals (General) Source Type: info

Mapping 3-Dimensional Neovessel Organization Steps Using Micro-Computed Tomography in a Murine Model of Hindlimb Ischemia.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: This study demonstrated that optimized mCT is a robust method for providing new insights into the 3D understanding of postischemic vessel formation. PMID: 19745199 [PubMed - as supplied by publisher] (Source: Arteriosclerosis, Thrombosis and Vascular Biology)
Source: Arteriosclerosis, Thrombosis and Vascular Biology - September 9, 2009 Category: Cardiology Authors: Oses P, Renault MA, Chauvel R, Leroux L, Allières C, Séguy B, Lamazière JM, Dufourcq P, Couffinhal T, Duplàa C Tags: Arterioscler Thromb Vasc Biol Source Type: journals

FDA Reviewing Safety Profile of Popular Weight Loss ProductsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Another weight loss drug has come under FDA scrutiny. The agency said Aug. 24 that it is reviewing the safety of orlistat after receiving reports of liver injury in patients using the drug, which is marketed as the prescription drug Xenical and the OTC medication Alli. (Source: AAFP Health of the Public)
Source: AAFP Health of the Public - September 9, 2009 Category: Primary Care Source Type: news

More children taking obesity drugsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
“The number of children on anti-obesity drugs has risen 15-fold in the last 10 years”, The Daily Telegraph reported. It said that a study of data from GPs between 1999 and 2006 shows up to 1,300 children and teenagers a year could be prescribed the drugs, even though they are not licensed for use by children. The newspaper said that most prescriptions “were for 14-year-olds, although 25 prescriptions were written for children under the age of 12”. This research looked at a selection of GP records from practices covering 5% of the population. It is a well-conducted study and the results are likely to be repres...
Source: NHS News Feed - September 3, 2009 Category: Consumer Health News Tags: Obesity Pregnancy/child Source Type: news

Rise in anti-obesity drug prescribing for children and adolescents in the UKEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: British Journal of Clinical Pharmacology Area: News According to a report in the British Journal of Clinical Pharmacology, the number of young people receiving prescriptions for anti-obesity drugs has increased 15-fold since 1999, but most stop using them before they could expect to see any benefit. These findings come from a population-based study investigating the use of unlicensed anti-obesity drugs (orlistat, sibutramine and rimonabant) in children and adolescents (0-18 years) in the UK using prescribing data (January 1999 and 31 December 2006) from the UK General Practice Research database. ...
Source: NeLM - News - September 2, 2009 Category: Drugs & Pharmacology Source Type: organizations

Effects of obesity reduction on cardiovascular risk factors: comparison of individual and group treatment--substudy of the Croatian Healthy Weight Loss Programme.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Prevention of obesity may help reduce the morbidity and mortality from cardiovascular diseases. In Croatia, over half of adult population is overweight. Aldo the basic medical principles of healthy weight-loss programmes are well known, it is believed that mainly because of the leak of successful therapeutic approach obesity remains the most challenging changeable cardiovascular risk factor in nowadays clinical practice. Objective of this Croatian Healthy Weight Loss Programme substudy was to determine effects and differences between the intensive group and intensive individual weight-loss program on weight loss and ca...
Source: Collegium Antropologicum - September 1, 2009 Category: Epidemiology Authors: Jovanović Z, Crncević-Orlić Z, Stimac D, Kokić S, Persić V, Ruzić T, Goll-Barić S Tags: Coll Antropol Source Type: journals

FDA Reviewing Liver Safety of Weight Loss DrugEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Reports of liver injury, including liver failure, in people taking over-the-counter and prescription orlistat for weight loss are being investigated by the Food and Drug Administration. (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - August 31, 2009 Category: Endocrinology Authors: Elizabeth MeChcatie Tags: News Source Type: news

Comparing clinician knowledge and online information regarding Alli (Orlistat)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Forum answers were comparable to clinicians’ answers with respect to accuracy and completeness, but answers from both sources were unsatisfactory. (Source: International Journal of Medical Informatics)
Source: International Journal of Medical Informatics - August 31, 2009 Category: Information Technology Authors: Stuart Nelson, Kevin O. Hwang, Elmer V. Bernstam Source Type: journals

US FDA reviewing safety of orlistatEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - August 31, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Concerns About Anti-Obesity Drug OrlistatEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
US authorities are investigating concerns that anti-obesity drug Orlistat may cause liver damage. Orlistat went on sale under the brand name Alli without the need for a prescription in the UK in April. The US Food and Drug Administration (FDA) has received more than 30 reports linking the drug to serious liver injury. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 31, 2009 Category: Consumer Health News Tags: Obesity / Weight Loss / Fitness Source Type: news

Medications for Obesity: Mechanisms and ApplicationsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Medications can significantly increase weight loss compared with placebo in most trials. In general, patients can expect a weight loss of 8% to 10% from baseline provided they adhere to the weight-loss program and take medications regularly. All medications have side effects that need to be considered before initiating treatment, however. For sibutramine, there is an increase in blood pressure and heart rate that may require discontinuation of the drug in a small percentage of patients. For orlistat, the principal side effect is gastrointestinal in origin resulting from the increased activity of the lower bowel. Cannabinoi...
Source: Clinics in Chest Medicine - August 27, 2009 Category: Respiratory Medicine Authors: George A. Bray Source Type: journals

FDA Reviewing Reports Linking Weight Loss Drug To Liver InjuriesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The US Food and Drug Administration (FDA) announced this week that it is reviewing reports of liver injury in people who took the weight loss drug orlistat, which is marketed as the prescription drug Xenical and over the counter (OTC) as Alli. However, the federal agency said in the meantime consumers should continue to use the product as prescribed or directed. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 27, 2009 Category: Consumer Health News Tags: Obesity / Weight Loss / Fitness Source Type: news

GlaxoSmithKline Statement Confirming alli SafetyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PITTSBURGH, Aug. 25 /PRNewswire/ -- The following is the GlaxoSmithKline statement in response to the FDA's Early Communication about the safety review of orlistat: "GSK stands firmly behind the safety and efficacy of alli. Our primary priority... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 26, 2009 Category: Pharmaceuticals Source Type: news

Obesity drug fears investigated (BBC news online, 25 August 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The anti-obesity drug Orlistat has been linked with liver damage. The US Food and Drug Administration are now reviewing the safety of the drug, which works by blocking fat absorption in the body. Full article (Source: Society for Endocrinology)
Source: Society for Endocrinology - August 26, 2009 Category: Endocrinology Source Type: organizations

Weightloss pill may damage liverEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A slimming drug available over the counter in the UK is being investigated for links to 32 cases of liver damage by the US Food and Drug Administration.The FDA began investigating orlistat, sold over the counter as Alli, and its potential links to liver damage earlier this year after concerns were raised about potentially harmful side effects. On Monday, the agency said it was assessing 32 reports of serious liver injury in patients, 27 of whom were hospitalised.Alli works by absorbing about a quarter of the fat from food and preventing it from being retained as extra weight. It went on sale in the UK in April and is avail...
Source: Guardian Unlimited Science - August 25, 2009 Category: Science Authors: Haroon Siddique Tags: Drugs Obesity Health & wellbeing Pharmaceuticals industry Business United States UK news World news Life and style Science GlaxoSmithKline The Guardian Source Type: news

Diet Drug Orlistat may be Associated with Liver DamageEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The weight loss drug orlistat, has been flagged by the FDA as a drug that bears watching. Orlistat is the generic name for the prescription drug Xenical and the over-the-counter... (Source: About Diabetes)
Source: About Diabetes - August 25, 2009 Category: Consumer Health Advice Source Type: consumer

The C type natriuretic peptide receptor tethers AHNAK1 at the plasma membrane to potentiate arachidonic acid induced calcium mobilization.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Arachidonic acid (AA) liberated from membrane phospholipids is known to activate phospholipase C gamma1 (PLCgamma1) concurrently with AHNAK in non-neuronal cells. The recruitment of AHNAK from the nucleus is required for it to activate PLCgamma1 at the plasma membrane. Here, we identify an atypical G protein coupled receptor, the C type natriuretic peptide receptor (NPR-C), as a protein binding partner for AHNAK1 in various cell types. Mass spectrometry and MASCOT analysis of excised bands from NPR-C immunoprecipitation studies revealed multiple signature peptides corresponding to AHNAK1. GST pulldown assays using GST-...
Source: American Journal of Physiology. Cell Physiology - August 25, 2009 Category: Cytology Authors: Alli AA, Gower WR Tags: Am J Physiol Cell Physiol Source Type: journals

FDA safety review of liver-related adverse events with orlistat (AlliT and XenicalT)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: FDA Area: News The US FDA is reviewing new safety information regarding reports of liver-related adverse events in patients taking orlistat (POM XenicalTand OTC AlliT). According to the FDA's Adverse Event Reporting System, 32 reports of serious liver injury, including 6 cases of liver failure, were submitted between 1999 and October 2008 in patients using orlistat; 30 of these reports occurred outside the US and 27 cases resulted in hospitalisation. The most commonly reported adverse events were jaundice, weakness and abdominal pain. In addition to the 32 reported cases, the FDA is reviewing...
Source: NeLM - Nutrition and Metabolism - August 25, 2009 Category: Nutrition Source Type: organizations